Clinical trial · Observational
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
NCT07484269CI-TRIAL-00106065PULSEnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- lutetium (177Lu) vipivotide tetraxetan
- description
- Patients with metastatic prostate cancer who are treated with lutetium (177Lu) vipivotide tetraxetan over a five-year followup period
Primary outcomes (1)
- measure
- Proportion and number of patients who receive any given number of lutetium (177Lu) vipivotide tetraxetan cycles
- timeFrame
- From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years
- description
- To describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among mPC patients
Secondary outcomes (31)
- measure
- Patient demographics
- timeFrame
- Baseline
- description
- Profile of patient demographics (e.g., age, race)
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion criteria: Age ≥ 18 years at index date * Diagnosis of mPC * PSMA positive * Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date Exclusion criterion: • Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
References
Publications (0)
Data not yet available
No reference posted for this study.